FA
ITOS

Forefront Analytics’s iTeos Therapeutics ITOS Stock Holding History

Forefront Analytics’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,061
Closed -$66.4K – 49
2025
Q1 		$66.4K Hold
11,061
– – 0.08% 42
2024
Q4 		$84.9K Buy
+11,061
New +$95K 0.04% 60

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Forefront Analytics's ITOS Position: Q2 2025 in Review

Forefront Analytics sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 11,061 shares — an estimated $66.4K sold.

Forefront Analytics first reported a position in ITOS in Q4 2024 and held it in 2 quarters. The position peaked at $84.9K in Q4 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Forefront Analytics reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Forefront Analytics sold 11,061 iTeos Therapeutics shares in Q2 2025, an estimated $66.4K.
  • Forefront Analytics first reported a position in iTeos Therapeutics in Q4 2024 and held it in 2 quarters.
  • Forefront Analytics's iTeos Therapeutics position peaked at $84.9K in Q4 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Forefront Analytics's 13F filing for Q2 2025, filed 24 Jul 2025.